Vancouver-based Zymeworks has added another marquee collaboration to its growing list of development partnerships.
A team at The Scripps Research Institute in La Jolla this week said they have identified four antibodies to target weaknesses in HIV, touting an "important advance" in HIV vaccine research that could assist in developing a vaccine.
Suzhou-based MabSpace Biosciences has raised $15 million in Series A funding from Lilly Asia Ventures to develop the biotech's technology for antibodies that break the tolerance of the immune system.
After signing on for a full lineup of combination drug studies with leading checkpoint inhibitors from Merck, AstraZeneca and Bristol-Myers Squibb, Eli Lilly is headed to the preclinical drawing board with a new collaboration to use ImaginAb's immune imaging agent IAB22M2C to study new T cell therapies for fighting cancer.
Eli Lilly has expanded its R&D partnership with China's Innovent Biologics, bringing in three potential immunotherapies for cancer and adding another $1 billion in potential value to the existing alliance.
Roche is investing in an early-stage project that takes a novel approach to treating autoimmune diseases, agreeing to pay up to $580 million for California's Adheron Therapeutics.
Sorrento Therapeutics, among the constellation of companies associated with billionaire Patrick Soon-Shiong, is again widening its R&D mission with a joint venture, teaming up with a California cancer center on some novel antibody technology.
Under-the-radar biotech startup Alector raised $32 million in Series C funds to support its early-stage work in neurodegenerative disease, recruiting some high-profile investors as it develops a novel approach to brain-destroying disorders.
Amgen is teaming up with Xencor through a heavily back-loaded deal worth as much as $1.7 billion, collaborating on 6 early-stage programs in immuno-oncology and inflammation.
Back at the beginning of 2014, a fast-growing Regeneron revealed that it had been building a new genetics research center that would zero in on carefully targeted diseases as it built new drug development programs from the ground up. Eighteen months later the big biotech says the effort--led by some top researchers wooed in to run the operation--has paid off with a clear target for a rare genetic bone disease. And they have an antibody in preclinical testing that could correct the disorder.